Expert Review of Vaccines最新文献_第7页

Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59 years at increased risk of severe RSV disease and those aged ≥60 years. 佐剂呼吸道合胞病毒预融合F蛋白（RSVPreF3）疫苗在50-59岁严重RSV疾病风险增加和年龄≥60岁的日本成年人中的成本-效果

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-02-11 DOI: 10.1080/14760584.2026.2626921

Kentaro Tajima, Eleftherios Zarkadoulas, Joost Simons, Daisuke Kurai, Mei Grace, Jonathan Graham, Yufan Ho, Frederik Verelst

{"title":"Cost-effectiveness of the adjuvanted respiratory syncytial virus prefusion F protein (RSVPreF3) vaccine in Japanese adults aged 50-59 years at increased risk of severe RSV disease and those aged ≥60 years.","authors":"Kentaro Tajima, Eleftherios Zarkadoulas, Joost Simons, Daisuke Kurai, Mei Grace, Jonathan Graham, Yufan Ho, Frederik Verelst","doi":"10.1080/14760584.2026.2626921","DOIUrl":"10.1080/14760584.2026.2626921","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) can cause substantial morbidity and mortality in adults aged 50-59 years at increased risk of severe RSV disease due to specific underlying conditions (i.e. '50-59 years at-increased-risk [AIR] population'), and in older adults aged ≥60 years (i.e. '≥60 years population').Research design and methods: A static multi-cohort Markov model estimated cost-effectiveness of adjuvanted RSVPreF3 vaccination versus no vaccination among the 50-59 years AIR and ≥60 years populations in Japan, over a five-year time horizon from a healthcare payer perspective. Japan-specific RSV epidemiology and healthcare resource utilization parameters were used; vaccine efficacy was derived from the phase 3 AReSVi-006 trial (NCT04886596).Results: Adjuvanted RSVPreF3 vaccination was cost-effective: in the 50-59 years AIR population, 49,280 RSV cases were prevented and 4333 quality-adjusted life years (QALYs) gained, at an incremental cost-effectiveness ratio (ICER) of Japanese yen (JPY) 2,770,558/QALY; in the ≥60 years population, 2,111,080 RSV cases were prevented and 205,543 QALYs gained, at an ICER of JPY 2,613,241/QALY. Vaccination was more cost-effective when including productivity losses from RSV-ARI. Scenario and sensitivity analyses results were robust.Conclusions: RSV vaccination may provide substantial health benefits and be a cost-effective intervention to reduce RSV burden in adults in Japan.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2626921"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146118349","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pneumococcal conjugate vaccines in older adults and immunocompromised individuals. 老年人和免疫功能低下个体的肺炎球菌结合疫苗。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2025-12-12 DOI: 10.1080/14760584.2025.2602525

Viravarn Luvira, Thundon Ngamprasertchai, Punnee Pitisuttithum

{"title":"Pneumococcal conjugate vaccines in older adults and immunocompromised individuals.","authors":"Viravarn Luvira, Thundon Ngamprasertchai, Punnee Pitisuttithum","doi":"10.1080/14760584.2025.2602525","DOIUrl":"10.1080/14760584.2025.2602525","url":null,"abstract":"Introduction: Pneumococcal disease leads to high morbidity and mortality, particularly in older adults and immunocompromised individuals. Many pneumococcal conjugated vaccines (PCVs) have become available. However, the immunogenicity, efficacy, and effectiveness data of these vaccines in older adults and immunocompromised individuals are limited.Areas covered: This review aims to critically examine the immune responses, immune correlations, efficacy, real-world effectiveness, and cost-effectiveness of pneumococcal conjugated vaccines (PCVs) in older adults and immunocompromised individuals.Expert opinion: A single dose of 20-valent or 21-valent PCV is recommended for older adults and immunocompromised individuals. Immune correlates of protection vary by serotype and race. An IgG level of 0.35 µg/mL is associated with protection, though this threshold is serotype-dependent. Opsonophagocytic assays, with a threshold of 1:8, remain the most reliable functional correlate of protection against invasive pneumococcal disease. Standardized immunological assays are essential for evaluating immune responses. High-valent PCVs have shown noninferior immunogenicity compared to PCV13, though geometric mean fold rises (GMFRs) for shared serotypes are slightly lower. Real-world effectiveness data are still needed, particularly in regions with differing serotype prevalence. Serotype surveillance is crucial when introducing PCV programs. Due to the high cost of higher-valent PCVs, many countries continue using PCV13 or PCV15 followed by PPSV23 for high-risk groups.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"1-10"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145713979","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Epidemiological shifts in coxsackievirus A-induced hand, foot, and mouth disease in China, 2008-2024. 2008-2024年中国柯萨奇病毒a致手足口病的流行病学变化

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-04-01 DOI: 10.1080/14760584.2026.2652927

Li Yu, Heng Zhao, Xin Zhao, Jingjing Wang, Yun Liao, Jun Li, Huiwen Zheng, Dandan Li, Heng Li, Haijing Shi, Longding Liu

{"title":"Epidemiological shifts in coxsackievirus A-induced hand, foot, and mouth disease in China, 2008-2024.","authors":"Li Yu, Heng Zhao, Xin Zhao, Jingjing Wang, Yun Liao, Jun Li, Huiwen Zheng, Dandan Li, Heng Li, Haijing Shi, Longding Liu","doi":"10.1080/14760584.2026.2652927","DOIUrl":"10.1080/14760584.2026.2652927","url":null,"abstract":"Introduction: Hand, foot, and mouth disease (HFMD) is primarily caused by enterovirus A71 (EV-A71) and coxsackievirus A (CV-A) serotypes. The introduction of the inactivated EV-A71 vaccine in China in 2016 significantly reduced EV-A71-related severe and fatal HFMD cases but did not confer cross-protection against other enteroviruses. Epidemiological data from China show that while the overall incidence of HFMD has declined since 2018, there has been a significant shift in the pathogen spectrum, with non-EV-A71 enteroviruses particularly CV-A6 and CV-A10 emerging as the predominant serotypes.Areas covered: To investigate the impact of enterovirus infections, we analyzed laboratory-confirmed HFMD case reported by the Chinese Center for Disease Control and Prevention (CDC) and provincial and municipal CDCs across China from 2008 through December 2024.Expert opinion: Post-vaccination, EV-A71 incidence declined markedly, while CV-A6, CV-A10, CV-A16, and CV-A4 gradually became predominant, exhibiting distinct geographic and seasonal distributions. These findings underscore the evolving HFMD epidemiology in China and highlight the need for multivalent vaccines and sustained surveillance to effectively control HFMD.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2652927"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147573044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Trends in vaccination in pharmacy and medical settings among Medicaid recipients in the United States, 2018-2023: a claims analysis. 2018-2023年美国医疗补助接受者在药房和医疗机构接种疫苗的趋势：索赔分析

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-08-14 DOI: 10.1080/14760584.2026.2715854

Amanda L Eiden, Yi Zheng, Kevin M Bakker, Dong Wang, Marcie Fisher-Borne

{"title":"Trends in vaccination in pharmacy and medical settings among Medicaid recipients in the United States, 2018-2023: a claims analysis.","authors":"Amanda L Eiden, Yi Zheng, Kevin M Bakker, Dong Wang, Marcie Fisher-Borne","doi":"10.1080/14760584.2026.2715854","DOIUrl":"10.1080/14760584.2026.2715854","url":null,"abstract":"Background: Medicaid beneficiaries typically have low vaccination rates, in part due to limited access. Pharmacies provide easy-to-access locations for vaccination.Research design and methods: This was a retrospective analysis of trends in pharmacy-based vaccination by age and race or ethnicity among Medicaid recipients aged ≥9 from 1 January 2018 (before the COVID-19 pandemic) to 31 December 2023. The percentage of all vaccinations administered at pharmacies and the overall percentage change in vaccination rates were determined.Results: With some exceptions, overall routine and seasonal vaccination rates remained lower in 2023 than in 2018-2019. This was observed for human papillomavirus (HPV), influenza, and tetanus-containing (Tdap/Td) vaccines in adolescents and for hepatitis A, influenza, meningococcal, pneumococcal, and Tdap/Td vaccines in various adult age groups. The percentage of routine and seasonal vaccinations administered at pharmacies increased over the study period among adults, with increases of 5.2-17.5 percentage points for hepatitis A, hepatitis B, HPV, meningococcal, pneumococcal, and tetanus-containing vaccines among those aged 19-49. Across age groups, pharmacy-based vaccination was most frequent in White enrollees, followed by Black and then Hispanic enrollees, with smaller differentials in adults aged ≥65.Conclusions: Generally overall vaccine administration rates declined in Medicaid beneficiaries; however, the proportion administered at pharmacies increased.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2715854"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148757902","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad. MenACYW-TT临床安全性的叙述性回顾：一种在美国和国外获得许可的破伤风类毒素结合的四价脑膜炎球菌疫苗

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-08-29 DOI: 10.1080/14760584.2026.2724614

Olga Syrkina, Mary Bausch-Jurken, Arlette Delgado, Jelena Jovanovic, Corwin A Robertson

{"title":"Narrative review of the clinical safety of MenACYW-TT: a quadrivalent meningococcal vaccine conjugated to tetanus toxoid licensed in the US and abroad.","authors":"Olga Syrkina, Mary Bausch-Jurken, Arlette Delgado, Jelena Jovanovic, Corwin A Robertson","doi":"10.1080/14760584.2026.2724614","DOIUrl":"10.1080/14760584.2026.2724614","url":null,"abstract":"Introduction: Routine meningococcal vaccination campaigns have substantially reduced the burden of invasive meningococcal disease in pediatric individuals, leading to relative increases in burden in older age groups. There is a need for safe, effective meningococcal vaccines that can be used across broad age ranges. MenACYW-TT, a quadrivalent tetanus-toxoid-conjugate meningococcal vaccine indicated for individuals aged ≥6 weeks, is one such option.Areas covered: This narrative review summarizes safety data from industry-sponsored pre- and post-licensure clinical trials of MenACYW-TT, including head-to-head studies with active comparators and coadministration studies with routine pediatric vaccines.Expert opinion: In >30 trials involving >17,000 participants, MenACYW-TT had a consistent safety profile across all age groups, from infants to older adults. The most frequent side effects were generally mild or moderate and transient; vaccine-related serious adverse events were rare (<0.1%). The safety of MenACYW-TT was comparable to that of other quadrivalent meningococcal conjugate vaccines. Coadministration did not materially affect the safety of MenACYW-TT or routine pediatric vaccines. Immunization remains an essential preventive strategy against the potentially life-threatening and life-altering consequences of invasive meningococcal disease. The favorable benefit-risk profile of MenACYW-TT reinforces the safety of licensed vaccines and can help to counter vaccine hesitancy.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2724614"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148857051","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Cohort studies may underestimate rare vaccine adverse events: evidence from stroke incidence following COVID-19 vaccination. 队列研究可能低估罕见的疫苗不良事件：来自COVID-19疫苗接种后卒中发生率的证据

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-08-24 DOI: 10.1080/14760584.2026.2720953

Hiam Chemaitelly, Naveed Akhtar, Salman Al Jerdi, Saadat Kamran, Sujatha Joseph, Deborah Morgan, Ryan Uy, Fatma B Abid, Abdullatif Al-Khal, Abdul-Badi Abou-Samra, Adeel A Butt, Laith J Abu-Raddad

{"title":"Cohort studies may underestimate rare vaccine adverse events: evidence from stroke incidence following COVID-19 vaccination.","authors":"Hiam Chemaitelly, Naveed Akhtar, Salman Al Jerdi, Saadat Kamran, Sujatha Joseph, Deborah Morgan, Ryan Uy, Fatma B Abid, Abdullatif Al-Khal, Abdul-Badi Abou-Samra, Adeel A Butt, Laith J Abu-Raddad","doi":"10.1080/14760584.2026.2720953","DOIUrl":"10.1080/14760584.2026.2720953","url":null,"abstract":"Background: The self-controlled case series (SCCS) design is widely used for short-term vaccine safety assessment but allows only indirect estimation of absolute risk differences. This study evaluated whether absolute measures should be estimated exclusively using cohort designs by comparing excess stroke incidence following COVID-19 vaccination in a nationwide cohort with previous estimates from an SCCS analysis.Methods: A nationwide retrospective cohort study was conducted in Qatar between 1 December 2020 and 11 April 2023. Stroke incidence during the 42 days following vaccination was compared between 1,111,939 vaccinated persons and an equal number of individually matched unvaccinated persons.Results: During follow-up, 8 strokes occurred in the vaccinated cohort and 19 in the unvaccinated cohort, corresponding to incidence rates of 0.2 (95% CI, 0.1-0.3) and 0.4 (95% CI, 0.2-0.6) per 100,000 person-weeks, respectively. The adjusted hazard ratio comparing vaccinated with unvaccinated individuals was 0.42 (95% CI, 0.18-0.96).Conclusion: These cohort findings suggesting a spurious protective effect contrast with SCCS results from the same and other populations, which indicate a small increase in post-vaccination stroke risk. This divergence may reflect healthy vaccinee bias in between-person comparisons, challenging the exclusive use of cohort designs for estimating absolute risk differences.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2720953"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148808437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile. 老年人接种二价呼吸道合胞病毒预融合F （RSVpreF）疫苗的临床和经济影响：智利成本效益分析

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-12 DOI: 10.1080/14760584.2026.2725347

Rafael Bolanos, Tomas Eduardo Abbott, Ali Shajarizadeh, Nishu Gaind, Ramandeep Kaur, Luka Ivkovic, Juan Francisco Falconi, Rengina Kefalogianni, Dino Sepulveda, Diana Mendes

{"title":"Clinical and economic impact of bivalent respiratory syncytial virus prefusion F (RSVpreF) vaccination in older adults: a cost-effectiveness analysis for Chile.","authors":"Rafael Bolanos, Tomas Eduardo Abbott, Ali Shajarizadeh, Nishu Gaind, Ramandeep Kaur, Luka Ivkovic, Juan Francisco Falconi, Rengina Kefalogianni, Dino Sepulveda, Diana Mendes","doi":"10.1080/14760584.2026.2725347","DOIUrl":"10.1080/14760584.2026.2725347","url":null,"abstract":"Background: Respiratory syncytial virus (RSV) is a major cause of lower respiratory tract disease in older adults in Chile. Chile's National Immunization Technical Advisory Group (NITAG) recommended RSV vaccination for adults aged ≥60 years with risk factors for severe illness. This study estimated the cost-effectiveness of bivalent RSVpreF vaccination among at-risk older adults in Chile.Research design and methods: A population-based Markov model projected RSV-related outcomes under no vaccination and RSVpreF vaccination over the cohort lifetime. Cost-effectiveness was assessed from healthcare and societal perspectives in 2025 Chilean Pesos (CLP) and US Dollars (US$), with costs and outcomes discounted at 3% annually. Sensitivity analyses tested the model robustness.Results: RSVpreF vaccination was projected to prevent 14,956 hospitalizations, 50,419 emergency department visits, and 124,849 physician office visits; avert CLP76 billion (US$82 million) in direct medical costs and CLP305 billion (US$328 million) in indirect costs; and generate 7,079 quality-adjusted life-years (QALYs). At a threshold of CLP15,977,348 (US$17,180) per QALY gained, the maximum cost-effective vaccine price was CLP100,480 (US$108) and CLP265,261 (US$285) from the healthcare and societal perspectives respectively.Conclusions: RSVpreF vaccination would reduce RSV burden and likely be cost-effective for older adults in Chile.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2725347"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148955217","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Correction. 修正。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-09-11 DOI: 10.1080/14760584.2026.2732404

引用次数: 0

The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysis. 澳大利亚成人呼吸道疫苗接种的社会经济价值：效益-成本分析。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2026-10-17 DOI: 10.1080/14760584.2026.2748741

Matthew Napier, Angus Macfarlane, Ellie Tunnicliffe, Simon Brassel, Camilla Cahill, Sally Ryan, Christoph Lohan, Valda Struwig, Jeffrey Vietri, Diana Mendes, Tianyan Hu, Lotte Steuten

{"title":"The socioeconomic value of adult respiratory vaccination in Australia: a benefit-cost analysis.","authors":"Matthew Napier, Angus Macfarlane, Ellie Tunnicliffe, Simon Brassel, Camilla Cahill, Sally Ryan, Christoph Lohan, Valda Struwig, Jeffrey Vietri, Diana Mendes, Tianyan Hu, Lotte Steuten","doi":"10.1080/14760584.2026.2748741","DOIUrl":"https://doi.org/10.1080/14760584.2026.2748741","url":null,"abstract":"Background: Pneumococcal disease, respiratory syncytial virus, influenza and COVID-19 cause a major burden of illness and death among adults, much of which is vaccine-preventable. We estimated the societal value of adult vaccination against these four pathogens in Australia.Research design and methods: We developed disease-specific static life table cohort models and conducted a societal-perspective benefit-cost analysis of adult respiratory vaccination, approximating those recommended by the Australian Technical Advisory Group on Immunization, relative to no vaccination. Mortality risk reductions were monetized using value of a statistical life (VSL) and value of a statistical life year (VSLY); avoided morbidity and productivity losses were also captured. Main outcomes were benefit-cost ratios (BCRs) and net monetary benefits (NMBs).Results: Over ten years, age and risk-based vaccination generated gross returns of $11.24 (VSL) and $5.69 (VSLY) per Australian dollar invested (net returns $10.24 and $4.69), with NMBs of $64.97 billion and $29.76 billion, averting 234,187 hospitalizations and 13,890 deaths. BCRs remained well above 1 across all scenarios.Conclusions: Adult respiratory vaccination shows strong societal returns. Improving coverage and extending eligibility offer the potential for further societal gains. Some simplifications in the model are likely to understate the value of vaccination while others may overstate it.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":"25 1","pages":"2748741"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"149215410","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Exploring determinants of vaccine hesitancy among healthcare professionals: a systematic literature review. 探索医疗保健专业人员中疫苗犹豫的决定因素：一项系统的文献综述。

IF 5.6 3区医学

Expert Review of Vaccines Pub Date : 2026-12-01 Epub Date: 2025-12-25 DOI: 10.1080/14760584.2025.2607479

Valeria Gabellone, Fabiana Nuccetelli, Elisa Gabrielli, Rosa Prato, Pierluigi Lopalco

{"title":"Exploring determinants of vaccine hesitancy among healthcare professionals: a systematic literature review.","authors":"Valeria Gabellone, Fabiana Nuccetelli, Elisa Gabrielli, Rosa Prato, Pierluigi Lopalco","doi":"10.1080/14760584.2025.2607479","DOIUrl":"10.1080/14760584.2025.2607479","url":null,"abstract":"Introduction: This systematic review aims to assess determinants of vaccine hesitancy (VH) among healthcare professionals, to identify knowledge gaps and inform targeted training programs.Research design and methods: A systematic search of PubMed and Scopus was conducted in February 2024. PRISMA criteria were applied, and methodological quality was assessed using a cross-sectional study evaluation tool. Studies addressing HCWs' VH determinants, including knowledge, attitudes, communication, and organizational factors, were included.Results: Out of 1394 records, 221 articles were included. Reported prevalence of VH among HCWs varied across studies, reflecting differences in professional roles, settings, and vaccines studied. Key determinants included gaps in knowledge, personal beliefs, organizational barriers, and communication skills. The review highlights the importance of evidence-based information, continuing education, and effective communication in addressing VH among HCWs.Conclusions: Educational and organizational interventions are essential to improve HCWs' knowledge, attitudes, and practices regarding vaccination. Strengthening vaccine education, fostering effective communication, and addressing organizational challenges can reduce hesitancy and support HCWs in promoting vaccination among patients. Future initiatives should consider the diversity of educational settings, professional roles, and training requirements across healthcare systems.","PeriodicalId":12326,"journal":{"name":"Expert Review of Vaccines","volume":" ","pages":"2607479"},"PeriodicalIF":5.6,"publicationDate":"2026-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145810080","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0